BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenstrm’s Macroglobulinemia – Business…
BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the European Commission (EC) approved BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenstrms macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. The approval is applicable to all 27 European Union (EU) member states, plus Iceland and Norway. BeiGene is working to make this new treatment option available to WM patients in the EU as quickly as possible.
BTK inhibition is an established mode of treatment for patients with WM, and the approval of BRUKINSA provides an important new option for patients with WM that may offer improved outcomes, said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. Patients and their physicians in the EU will soon have access to an innovative medicine that has potential to offer deep and durable responses and improved tolerability, as seen in the ASPEN trial.
The EC approval for BRUKINSA follows a positive opinion granted in September by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), based on the results of the ASPEN trial. Although the primary endpoint of statistical superiority related to deep response, very good partial response (VGPR) or better, was not met, BRUKINSA demonstrated clinical benefit with advantages in safety compared to ibrutinib.1 Read more about the positive CHMP opinion and ASPEN trial results here.
With BRUKINSA now approved in the EU, we continue to execute on our commitment of making this potentially best-in-class BTK inhibitor available for more patients around the world who may benefit, said Jane Huang, M.D., Chief Medical Officer, Haematology at BeiGene. BRUKINSA was designed to maximize BTK occupancy and minimize off-target effects and has demonstrated efficacy and advantages in safety and tolerability over ibrutinib in the ASPEN trial. We believe BRUKINSA will become the preferred treatment option among patients with WM and their physicians.
We have built a strong team in Europe that is committed to creating access to BRUKINSA for patients living with WM, said Gerwin Winter, Senior Vice President, Head of Commercial, Europe at BeiGene. This approval by the European Commission is a significant milestone for BeiGenes expansion in the region, representing another step towards BeiGenes goal of increasing access to innovative oncology medicines globally.
About Waldenstrms Macroglobulinemia
Waldenstrms macroglobulinemia (WM) is a generally indolent and relatively rare B-cell malignancy characterized by bone marrow infiltration with monoclonal immunoglobulin M (IgM) secreting lymphoplasmacytic cells. WM represents approximately one percent of all non-Hodgkins lymphomas and typically progresses slowly after diagnosis.2 The disease usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved.3 Throughout Europe, the estimated incidence rate of WM is approximately seven out of every one million men and four out of every one million women.4
About the ASPEN trial
The Phase 3 randomized, open-label, multicentre ASPEN clinical trial (NCT03053440) evaluated BRUKINSA (zanubrutinib) versus ibrutinib in patients with relapsed or refractory (R/R) WM or treatment-nave (TN) WM considered unsuitable for treatment with chemoimmunotherapy. The primary objective was to establish superiority of BRUKINSA compared to ibrutinib as demonstrated by the proportion of patients achieving complete response or very good partial response. Secondary endpoints included major response rate (MRR), duration of response (DoR) and progression-free survival (PFS), and safety, measured by incidence, timing and severity of treatment-emergent adverse events. The pre-specified analysis populations for the trial included the overall population (n=201), of which the majority were R/R patients (n=164). Exploratory endpoints included quality of life measures.
As assessed by an independent review committee (IRC) based on the modified Sixth International Workshop on Waldenstrms Macroglobulinemia (IWWM-6) response criteria (Treon 2015), the combined rate of complete response (CR) and VGPR in the overall intention-to-treat (ITT) population was 28% with BRUKINSA (95% CI: 20, 38), compared to 19% with ibrutinib (95% CI: 12, 28). While this difference was not statistically significant, BRUKINSA did achieve numerically higher VGPR rates and trends towards increased response quality.1
In the ASPEN trial, BRUKINSA demonstrated a more favorable safety profile compared to ibrutinib with lower frequency of adverse reactions that have raised concern with BTK inhibitors, including atrial fibrillation or flutter (2% vs. 15%), minor bleeding (49% vs. 59%) and major hemorrhage (6% vs. 9%). Despite higher rates of grade 3 neutropenia, patients on BRUKINSA did not demonstrate higher rates of infection as compared to those receiving ibrutinib. Of the 101 patients with WM treated with BRUKINSA, 4% of patients discontinued due to adverse events, and adverse events leading to dose reduction occurred in 14% of patients.1
The study includes three arms in two cohorts, a randomized cohort (Cohort 1, N=201) consisting of patients with a MYD88 mutation (MYD88MUT) and a non-randomized cohort (Cohort 2, N=28) in which patients with MYD88 wild-type (MYD88WT) received BRUKINSA because historic data indicated they were unlikely to benefit from ibrutinib. The randomized Cohort 1 enrolled 102 patients (including 83 R/R patients and 19 TN patients) in the BRUKINSA arm and 99 patients (including 81 R/R patients and 18 TN patients) in the ibrutinib arm. Patients in the BRUKINSA arm were assigned to receive BRUKINSA 160 mg twice daily (BID) and patients in the ibrutinib arm received 420 mg of ibrutinib once daily (QD).
About BRUKINSA
BRUKINSA (zanubrutinib) is a small molecule inhibitor of Brutons tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease relevant tissues.
BRUKINSA is now approved in the United States, China, the European Union and nine other countries and regions. To date, more than 20 marketing authorization applications have been submitted for BRUKINSA for various indications.
Safety Information
The most commonly occurring adverse reactions (20%) were neutropenia (56.2%), thrombocytopenia (45.1%), upper respiratory tract infection (44.3%), hemorrhage/hematoma (32.2%), rash (29.8%), bruising (29.1%), anemia (28.9%), musculoskeletal pain (24.3%), diarrhea (23.6%), pneumonia (22.1%) and cough (21.7%).
The most common Grade 3 or higher adverse reactions (>5%) were neutropenia (28.0%), pneumonia (11.6%), thrombocytopenia (11.4%), and anemia (6.9%).
Of the 779 patients treated with zanubrutinib, 3.6% of patients discontinued treatment due to adverse reactions. The most frequent adverse reaction leading to treatment discontinuation was pneumonia (1.8%). Adverse reaction leading to dose reduction occurred in 4.9% of patients.
The recommended total daily dose of zanubrutinib is 320 mg. The daily dose may be taken either once daily (four 80 mg capsules) or divided into two doses of 160 mg twice daily (two 80 mg capsules).
BeiGene Oncology
BeiGene is committed to advancing best and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. We have a growing R&D team of approximately 2,750 colleagues dedicated to advancing more than 90 ongoing or planned clinical trials involving more than 14,000 patients and healthy volunteers. Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions. Haematology-oncology and solid tumour targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA in the United States, China, the EU, Canada, Australia, and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab as well as the PARP inhibitor pamiparib in China.
BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen and Bristol Myers Squibb. We also plan to address greater areas of unmet need globally through our collaborations including with Amgen, Bio-Thera, EUSA Pharma, Mirati Therapeutics, Seagen, and Zymeworks. BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. To learn more about BeiGene, please visit http://www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the planned commercialization and market access of BRUKINSA in the European Union and additional development, regulatory filings and potential approvals in other markets, the potential for BRUKINSA to be a best-in-class BTK inhibitor, the potential for BRUKINSA to provide improved clinical benefits with advantages in safety, the potential for BRUKINSA to become the preferred treatment option among patients with WM and their physicians, the potential commercial opportunity for BRUKINSA, and BeiGenes plans, commitments, aspirations and goals under the headings BeiGene Oncology and About BeiGene. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on the Companys clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
* BRUKINSA is approved in the following indications and regions:
a. This indication was approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
b. This indication was approved under conditional approval. Complete approval for this indication may be contingent upon results from ongoing randomized, controlled confirmatory clinical trials.
References:
1. Tam, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrm macroglobulinemia: the ASPEN study. Blood. October 2020. 136(18): 2038-2050.
2. Lymphoma Research Foundation. Getting the Facts: Waldenstrm Macroglobulinemia. Available at https://lymphoma.org/wp-content/uploads/2020/09/LRF-Waldenstrom-Macroglobulinemia_Factsheet.pdf. Updated 2020.
3. Lymphoma Research Foundation. Available at https://lymphoma.org/aboutlymphoma/nhl/wm/. Accessed December 2020.
4. Buske, C, et al. Treatment and outcome patterns in European patients with Waldenstrms macroglobulinaemia: a large, observational, retrospective chart review. The Lancet Haematology 2018; 5: e0299-309.
See the article here:
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenstrm's Macroglobulinemia - Business...
- European Union's Wheat Market Expected to Reach 118M Tons and $34.3B by 2035 - IndexBox - July 20th, 2025 [July 20th, 2025]
- European Union's Nail and Bolt Market to Grow at +1.2% CAGR Over the Next Decade - IndexBox - July 20th, 2025 [July 20th, 2025]
- European Union's HVAC Equipment Market to Grow at +1.0% CAGR, Reaching 932M Units by 2035 - IndexBox - July 20th, 2025 [July 20th, 2025]
- European Union's Vacuum Pumps and Air or Gas Compressors Market to Witness 1.8% CAGR Growth from 2024 to 2035 - IndexBox - July 20th, 2025 [July 20th, 2025]
- European Union's Confectionery Market to Experience Slow Growth with CAGR of +1.2% - IndexBox - July 20th, 2025 [July 20th, 2025]
- European Union increasing pressure on Russia to end invasion of Ukraine - WFAA - July 20th, 2025 [July 20th, 2025]
- European Union's Flat Hot-Rolled Steel in Coils Market to Grow at +1.4% CAGR, Reaching 37M Tons by 2035 - IndexBox - July 20th, 2025 [July 20th, 2025]
- The European Union Passed Its Artificial Intelligence Bill. Will It Enforce It? - Billboard - July 20th, 2025 [July 20th, 2025]
- Solidarity visit to Ukraine: COMECE witnesses the scale of human loss - The Catholic Church in the European Union - July 20th, 2025 [July 20th, 2025]
- Briefing paper for the 13th European Union-Vietnam human rights dialogue - fidh.org - July 18th, 2025 [July 18th, 2025]
- How Important Are the Turkic States to the European Union, and in What Areas? - Hungarian Conservative - July 16th, 2025 [July 16th, 2025]
- European Union threatens tariff retaliation after Trumps trade move - CGTN America - July 16th, 2025 [July 16th, 2025]
- European Union Responds to Trump Tariffs by Targeting Boeing, U.S. Cars and Bourbon - CPA Practice Advisor - July 16th, 2025 [July 16th, 2025]
- EU expands sanctions against Russia for destabilization in the European Union and Ukraine - - July 16th, 2025 [July 16th, 2025]
- Nine Iranian individuals and entities added to the European Union's new sanctions list - Iran Focus - July 16th, 2025 [July 16th, 2025]
- European Union to delay retaliatory tariffs on U.S. goods in hopes of reaching deal - CBS News - July 14th, 2025 [July 14th, 2025]
- Trump announces tariffs of 30% on Mexico and the European Union - CNN - July 14th, 2025 [July 14th, 2025]
- Video Trump threatens the European Union and Mexico with new tariffs - ABC News - Breaking News, Latest News and Videos - July 14th, 2025 [July 14th, 2025]
- European Union on the ropes as Trump and China turn the screws - South China Morning Post - July 14th, 2025 [July 14th, 2025]
- Trump announces tariffs on European Union, Mexico starting in August - CBS News - July 14th, 2025 [July 14th, 2025]
- EUR/USD rises to near 1.1700 due to Trumps tariff threats on European Union - FXStreet - July 14th, 2025 [July 14th, 2025]
- Trump: European Union in discussions with us on trade - Forex Factory - July 14th, 2025 [July 14th, 2025]
- Trump announces 30% tariffs on Mexico and European Union starting Aug. 1 - CBS News - July 14th, 2025 [July 14th, 2025]
- Trump Announces 30% Tariffs On European Union And Mexico As Trade War Ramps Up Again - HuffPost - July 14th, 2025 [July 14th, 2025]
- Trump announces 30% tariff on European Union and Mexico - The Economic Times - July 14th, 2025 [July 14th, 2025]
- Trump announces 30 percent tariffs against European Union and Mexico - The Boston Globe - July 12th, 2025 [July 12th, 2025]
- Trump announces shocking new tariffs for European Union and Mexico that will have a major impact - UNILAD - July 12th, 2025 [July 12th, 2025]
- Trump announces tariffs of 30% on Mexico and the European Union - KTVZ - July 12th, 2025 [July 12th, 2025]
- Israel, European Union reach deal on more aid, fuel deliveries to Gaza - The Washington Post - July 12th, 2025 [July 12th, 2025]
- Trump hits the European Union (EU) with a 30% tariff, starting on August 1 - Forexlive | Forex News, Technical Analysis & Trading Tools - July 12th, 2025 [July 12th, 2025]
- Life-cycle greenhouse gas emissions from passenger cars in the European Union: A 2025 update and key factors to consider - International Council on... - July 12th, 2025 [July 12th, 2025]
- Trump's 30% tariff threat on European Union goods a negotiation tactic: EU officials - Mint - July 12th, 2025 [July 12th, 2025]
- European Union's Dental Fittings Market to Reach 14M Units and $13.1B in Value by 2035 - IndexBox - July 12th, 2025 [July 12th, 2025]
- Bigger, better funded and focused on public goods: how to revamp the European Union budget - Bruegel - July 12th, 2025 [July 12th, 2025]
- European Union Special Representatives for the Sahel and the Horn of Africa visit Addis Ababa - EEAS - July 8th, 2025 [July 8th, 2025]
- Iceland : The 28th member state of the European Union ? Le Taurillon - treffpunkteuropa.de - July 8th, 2025 [July 8th, 2025]
- European Union's Caramel Market to Reach 606K Tons and $838M by 2035 - IndexBox - July 6th, 2025 [July 6th, 2025]
- European Union's Threaded Steel Articles Market to Grow at +1.4% CAGR, Reaching $4.4B by 2035 - IndexBox - July 6th, 2025 [July 6th, 2025]
- The European Union awards an additional 14.8 million in Aid to UNICEF to support the most vulnerable children and strengthen disaster preparedness in... - July 4th, 2025 [July 4th, 2025]
- Speech by President Antnio Costa at the opening ceremony of the Danish Presidency of the Council of the European Union - consilium.europa.eu - July 4th, 2025 [July 4th, 2025]
- Deepening structural reforms and reprioritising public spending can boost growth in the European Union - OECD - July 4th, 2025 [July 4th, 2025]
- Now Unfolding The Impact Of Russias Military Priorities On International Travel: Insights For US, China, European Union And CIS Markets: Here Is What... - July 4th, 2025 [July 4th, 2025]
- European Union's Butan-1-ol Market to Experience Slight Growth with +0.3% CAGR in Volume and +1.6% CAGR in Value from 2024 to 2035 - IndexBox - July 4th, 2025 [July 4th, 2025]
- China and the European Union Hold the 13th Round of High-level Strategic Dialogue - fmprc.gov.cn - July 4th, 2025 [July 4th, 2025]
- European Union's Cobalt Oxides and Hydroxides Market Expected to Grow steadily at +2.3% CAGR over the Next Decade - IndexBox - July 4th, 2025 [July 4th, 2025]
- European Union's Lubricating Oil Additives Market to Expand at a CAGR of +2.4% Through 2035, Reaching $103.1B in Market Value - IndexBox - July 2nd, 2025 [July 2nd, 2025]
- New spokesperson for the European Union Mission in Mozambique is from Minho - EEAS - July 2nd, 2025 [July 2nd, 2025]
- European Union nations call for stricter limits on sperm donation - Live Action | Pro-Life - June 29th, 2025 [June 29th, 2025]
- European Union's Cheese Market: Increasing Demand for Grated, Powdered, and Blue-Veined Cheeses to Drive Market Growth to 7M tons and $48.4B by 2035 -... - June 29th, 2025 [June 29th, 2025]
- European Union's Silver Market to See Slight Growth with +1.3% CAGR Driving Consumption Trends - IndexBox - June 29th, 2025 [June 29th, 2025]
- European Union's Grape Market to Witness Mild Growth with CAGR of +0.5% from 2024 to 2035 - IndexBox - June 29th, 2025 [June 29th, 2025]
- European Union Set to Redefine Budget Air Travel with Ambitious Policy Guaranteeing Free Carry-On Luggage and Greater Passenger Freedom on All EU and... - June 29th, 2025 [June 29th, 2025]
- European Union's Iron and Steel Slabs, Billets, and Blooms Market to Exhibit Slight Growth with CAGR of +0.4% through 2035 - IndexBox - June 29th, 2025 [June 29th, 2025]
- The United States has submitted a fresh trade deal proposal to the European Union - Forexlive | Forex News, Technical Analysis & Trading Tools - June 29th, 2025 [June 29th, 2025]
- Why Apple is revamping its App Store terms in the European Union - Fast Company - June 28th, 2025 [June 28th, 2025]
- Fiala: The European Union should not terminate the association agreement with Israel - European Newsroom - June 28th, 2025 [June 28th, 2025]
- European Union's Nitric and Sulphonitric Acids Market to Reach 1.5M Tons and $586M by 2035 - IndexBox - June 28th, 2025 [June 28th, 2025]
- European Union's Aniline Derivatives Market Expected to See +1.5% CAGR Growth Over Next Decade - IndexBox - June 28th, 2025 [June 28th, 2025]
- One-sided account of Israels actions in Gaza, Bnai Brith says of European Union report - JNS.org - June 28th, 2025 [June 28th, 2025]
- Importing Conflict into the European Union Not the Way to Peace, Hungarian PMs Political Director Says - The European Conservative - June 28th, 2025 [June 28th, 2025]
- After NATO Deal, How Far Will European Union Go For Trade Peace With Donald Trump - NDTV - June 28th, 2025 [June 28th, 2025]
- European Union divided over response to suspected Israeli rights breaches - Reuters - June 24th, 2025 [June 24th, 2025]
- The European Union and Canada open a new chapter in their cooperation - European Commission - June 24th, 2025 [June 24th, 2025]
- European Union military engagement in the Western Balkans: peacekeeping or strategic containment? EUs mission EUFOR Althea case study - PubAffairs... - June 24th, 2025 [June 24th, 2025]
- Lavrov announced the manifestation of rebellion in the controlled "herd" of NATO and of the European Union - EADaily - June 24th, 2025 [June 24th, 2025]
- Spain will ask the European Union to suspend the association agreement with Israel - Pressenza - International Press Agency - June 24th, 2025 [June 24th, 2025]
- European Union divided over response to suspected Israeli rights breaches - The Japan Times - June 24th, 2025 [June 24th, 2025]
- Israels appetite for war in Gaza threatens its relationship with the European Union - The Guardian - June 24th, 2025 [June 24th, 2025]
- Hybrid launch of 'The Routledge Guide to the European Union (2nd edition)' with Ian Bond, Mark Leonard and Armida van Rij - Centre for European Reform... - June 24th, 2025 [June 24th, 2025]
- The role of services of general interest (SGI) for competitiveness, social cohesion and democracy in the European Union - EESC - June 24th, 2025 [June 24th, 2025]
- European Union's Boring or Sinking Machinery Market to Reach 44K Units and $2.2B Value by 2035 - IndexBox - June 24th, 2025 [June 24th, 2025]
- European Union: AI Partnerships and DMA Enforcement Top of the Agenda for European Regulators - Wilson Sonsini - June 22nd, 2025 [June 22nd, 2025]
- European Union's Beverage Filtration Machinery Market to Reach 1.2M Units and $612M by 2035 - IndexBox - June 22nd, 2025 [June 22nd, 2025]
- European Union's Hydraulic Press Market Expected to Grow with 289K Units and $2.4B Value by 2035 - IndexBox - June 22nd, 2025 [June 22nd, 2025]
- Statement by the Ministers of Foreign Affairs of France, Germany, and the United Kingdom, together with the High Representative of the European Union... - June 22nd, 2025 [June 22nd, 2025]
- Rare earth access is the European Union's priority at China summit - Reuters - June 20th, 2025 [June 20th, 2025]
- Germany, Italy, Netherlands, Spain, Czech Republic, Denmark and Twenty One Countries in European Union Threatening to Suspend Israel Schengen Visa... - June 20th, 2025 [June 20th, 2025]
- European Union's Lifts and Elevators Market to Grow at a CAGR of +0.9% through 2035, Expected to Reach 665K Units - IndexBox - June 20th, 2025 [June 20th, 2025]
- European Union's Packaging Machinery Market to Increase at a CAGR of +2.2% Reaching $6.3B by 2035 - IndexBox - June 20th, 2025 [June 20th, 2025]
- The European Union announced the rejection of Russian gas at the wrong time: the price is approaching $ 500 - EADaily - June 20th, 2025 [June 20th, 2025]